As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...

From denials and payer plans for unilateral downcoding to 340B legal battles, the most-read stories of 2025 reveal a revenue cycle under pressure, and the strategies leaders are using to stay afloat.

As regulatory pressure mounts and workforce shortages persist, Louisville, Ky.-based Baptist Health System is positioning pharmacy as a safeguard for medication access and a driver of system growth.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

A late 2021 survey of hospitals participating in the 340B drug pricing program suggests pharma industry leaders’ recent restrictions on drug discounts are costing safety net hospitals hundreds of ...

While more than 2,900 U.S. hospitals hold tax-exempt status as nonprofits, critics argue they have undergone a “mission drift ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their ...